In addition, IL-22 significantly impaired sorafenib-mediated antitumor effect in HCC by activating tumor cell-intrinsic STAT3/CD155 axis to inhibit the cellular toxicity of sorafenib and NK cell -mediated killing to HCC cells. Here, IL22 is linked to hepatocellular carcinoma.